The vaginal acquisition and dissemination of HIV-1 infection in a novel transgenic mouse model is facilitated by coinfection with herpes simplex virus 2 and is inhibited by microbicide treatment

Kieran Seay, Nazanin Khajoueinejad, Jian Hua Zheng, Patrick Kiser, Christina Ochsenbauer, John C. Kappes, Betsy Herold, Harris Goldstein

Research output: Contribution to journalArticle

9 Citations (Scopus)

Abstract

Epidemiological studies have demonstrated that herpes simplex virus 2 (HSV-2) infection significantly increases the risk ofHIV-1 acquisition, thereby contributing to the expanding HIV-1 epidemic. To investigate whether HSV-2 infection directly facilitatesmucosal HIV-1 acquisition, we used our transgenic hCD4/R5/cT1 mouse model which circumvents major entry and transcriptionblocks preventing murine HIV-1 infection by targeting transgenic expression of human CD4, CCR5, and cyclin T1genes to CD4<sup>+</sup> T cells and myeloid-committed cells. Productive infection of mucosal leukocytes, predominantly CD4<sup>+</sup> T cells,was detected in all hCD4/R5/cT1 mice intravaginally challenged with an HIV-1 infectious molecular clone, HIV-Du151.2env-NLuc, which expresses an env gene (C.Du151.2) cloned from an acute heterosexually infected woman and a NanoLuc luciferasereporter gene. Lower genital tract HIV-1 infection after HIV-Du151.2env-NLuc intravaginal challenge was increased ~4-fold inhCD4/R5/cT1 mice coinfected with HSV-2. Furthermore, HIV-1 dissemination to draining lymph nodes was detected only inHSV-2-coinfected mice. HSV-2 infection stimulated local infiltration and activation of CD4<sup>+</sup> T cells and dendritic cells, likelycontributing to the enhanced HIV-1 infection and dissemination in HSV-2-coinfected mice. We then used this model to demonstratethat a novel gel containing tenofovir disoproxil fumarate (TDF), the more potent prodrug of tenofovir (TFV), but not theTFV microbicide gel utilized in the recent CAPRISA 004, VOICE (Vaginal and Oral Interventions to Control the Epidemic), andFACTS 001 clinical trials, was effective as preexposure prophylaxis (PrEP) to completely prevent vaginal HIV-1 infection in almosthalf of HSV-2-coinfected mice. These results also support utilization of hCD4/R5/cT1 mice as a highly reproducible immunocompetentpreclinical model to evaluate HIV-1 acquisition across the female genital tract.

Original languageEnglish (US)
Pages (from-to)9559-9570
Number of pages12
JournalJournal of Virology
Volume89
Issue number18
DOIs
StatePublished - 2015

Fingerprint

Human herpesvirus 2
Human Herpesvirus 2
Anti-Infective Agents
Human immunodeficiency virus 1
Coinfection
mixed infection
Transgenic Mice
HIV Infections
HIV-1
anti-infective agents
animal models
genetically modified organisms
Tenofovir
infection
mice
Virus Diseases
Therapeutics
T-lymphocytes
T-Lymphocytes
Gels

ASJC Scopus subject areas

  • Immunology
  • Virology

Cite this

The vaginal acquisition and dissemination of HIV-1 infection in a novel transgenic mouse model is facilitated by coinfection with herpes simplex virus 2 and is inhibited by microbicide treatment. / Seay, Kieran; Khajoueinejad, Nazanin; Zheng, Jian Hua; Kiser, Patrick; Ochsenbauer, Christina; Kappes, John C.; Herold, Betsy; Goldstein, Harris.

In: Journal of Virology, Vol. 89, No. 18, 2015, p. 9559-9570.

Research output: Contribution to journalArticle

@article{992631e871394924b82035fcc61d64cf,
title = "The vaginal acquisition and dissemination of HIV-1 infection in a novel transgenic mouse model is facilitated by coinfection with herpes simplex virus 2 and is inhibited by microbicide treatment",
abstract = "Epidemiological studies have demonstrated that herpes simplex virus 2 (HSV-2) infection significantly increases the risk ofHIV-1 acquisition, thereby contributing to the expanding HIV-1 epidemic. To investigate whether HSV-2 infection directly facilitatesmucosal HIV-1 acquisition, we used our transgenic hCD4/R5/cT1 mouse model which circumvents major entry and transcriptionblocks preventing murine HIV-1 infection by targeting transgenic expression of human CD4, CCR5, and cyclin T1genes to CD4+ T cells and myeloid-committed cells. Productive infection of mucosal leukocytes, predominantly CD4+ T cells,was detected in all hCD4/R5/cT1 mice intravaginally challenged with an HIV-1 infectious molecular clone, HIV-Du151.2env-NLuc, which expresses an env gene (C.Du151.2) cloned from an acute heterosexually infected woman and a NanoLuc luciferasereporter gene. Lower genital tract HIV-1 infection after HIV-Du151.2env-NLuc intravaginal challenge was increased ~4-fold inhCD4/R5/cT1 mice coinfected with HSV-2. Furthermore, HIV-1 dissemination to draining lymph nodes was detected only inHSV-2-coinfected mice. HSV-2 infection stimulated local infiltration and activation of CD4+ T cells and dendritic cells, likelycontributing to the enhanced HIV-1 infection and dissemination in HSV-2-coinfected mice. We then used this model to demonstratethat a novel gel containing tenofovir disoproxil fumarate (TDF), the more potent prodrug of tenofovir (TFV), but not theTFV microbicide gel utilized in the recent CAPRISA 004, VOICE (Vaginal and Oral Interventions to Control the Epidemic), andFACTS 001 clinical trials, was effective as preexposure prophylaxis (PrEP) to completely prevent vaginal HIV-1 infection in almosthalf of HSV-2-coinfected mice. These results also support utilization of hCD4/R5/cT1 mice as a highly reproducible immunocompetentpreclinical model to evaluate HIV-1 acquisition across the female genital tract.",
author = "Kieran Seay and Nazanin Khajoueinejad and Zheng, {Jian Hua} and Patrick Kiser and Christina Ochsenbauer and Kappes, {John C.} and Betsy Herold and Harris Goldstein",
year = "2015",
doi = "10.1128/JVI.01326-15",
language = "English (US)",
volume = "89",
pages = "9559--9570",
journal = "Journal of Virology",
issn = "0022-538X",
publisher = "American Society for Microbiology",
number = "18",

}

TY - JOUR

T1 - The vaginal acquisition and dissemination of HIV-1 infection in a novel transgenic mouse model is facilitated by coinfection with herpes simplex virus 2 and is inhibited by microbicide treatment

AU - Seay, Kieran

AU - Khajoueinejad, Nazanin

AU - Zheng, Jian Hua

AU - Kiser, Patrick

AU - Ochsenbauer, Christina

AU - Kappes, John C.

AU - Herold, Betsy

AU - Goldstein, Harris

PY - 2015

Y1 - 2015

N2 - Epidemiological studies have demonstrated that herpes simplex virus 2 (HSV-2) infection significantly increases the risk ofHIV-1 acquisition, thereby contributing to the expanding HIV-1 epidemic. To investigate whether HSV-2 infection directly facilitatesmucosal HIV-1 acquisition, we used our transgenic hCD4/R5/cT1 mouse model which circumvents major entry and transcriptionblocks preventing murine HIV-1 infection by targeting transgenic expression of human CD4, CCR5, and cyclin T1genes to CD4+ T cells and myeloid-committed cells. Productive infection of mucosal leukocytes, predominantly CD4+ T cells,was detected in all hCD4/R5/cT1 mice intravaginally challenged with an HIV-1 infectious molecular clone, HIV-Du151.2env-NLuc, which expresses an env gene (C.Du151.2) cloned from an acute heterosexually infected woman and a NanoLuc luciferasereporter gene. Lower genital tract HIV-1 infection after HIV-Du151.2env-NLuc intravaginal challenge was increased ~4-fold inhCD4/R5/cT1 mice coinfected with HSV-2. Furthermore, HIV-1 dissemination to draining lymph nodes was detected only inHSV-2-coinfected mice. HSV-2 infection stimulated local infiltration and activation of CD4+ T cells and dendritic cells, likelycontributing to the enhanced HIV-1 infection and dissemination in HSV-2-coinfected mice. We then used this model to demonstratethat a novel gel containing tenofovir disoproxil fumarate (TDF), the more potent prodrug of tenofovir (TFV), but not theTFV microbicide gel utilized in the recent CAPRISA 004, VOICE (Vaginal and Oral Interventions to Control the Epidemic), andFACTS 001 clinical trials, was effective as preexposure prophylaxis (PrEP) to completely prevent vaginal HIV-1 infection in almosthalf of HSV-2-coinfected mice. These results also support utilization of hCD4/R5/cT1 mice as a highly reproducible immunocompetentpreclinical model to evaluate HIV-1 acquisition across the female genital tract.

AB - Epidemiological studies have demonstrated that herpes simplex virus 2 (HSV-2) infection significantly increases the risk ofHIV-1 acquisition, thereby contributing to the expanding HIV-1 epidemic. To investigate whether HSV-2 infection directly facilitatesmucosal HIV-1 acquisition, we used our transgenic hCD4/R5/cT1 mouse model which circumvents major entry and transcriptionblocks preventing murine HIV-1 infection by targeting transgenic expression of human CD4, CCR5, and cyclin T1genes to CD4+ T cells and myeloid-committed cells. Productive infection of mucosal leukocytes, predominantly CD4+ T cells,was detected in all hCD4/R5/cT1 mice intravaginally challenged with an HIV-1 infectious molecular clone, HIV-Du151.2env-NLuc, which expresses an env gene (C.Du151.2) cloned from an acute heterosexually infected woman and a NanoLuc luciferasereporter gene. Lower genital tract HIV-1 infection after HIV-Du151.2env-NLuc intravaginal challenge was increased ~4-fold inhCD4/R5/cT1 mice coinfected with HSV-2. Furthermore, HIV-1 dissemination to draining lymph nodes was detected only inHSV-2-coinfected mice. HSV-2 infection stimulated local infiltration and activation of CD4+ T cells and dendritic cells, likelycontributing to the enhanced HIV-1 infection and dissemination in HSV-2-coinfected mice. We then used this model to demonstratethat a novel gel containing tenofovir disoproxil fumarate (TDF), the more potent prodrug of tenofovir (TFV), but not theTFV microbicide gel utilized in the recent CAPRISA 004, VOICE (Vaginal and Oral Interventions to Control the Epidemic), andFACTS 001 clinical trials, was effective as preexposure prophylaxis (PrEP) to completely prevent vaginal HIV-1 infection in almosthalf of HSV-2-coinfected mice. These results also support utilization of hCD4/R5/cT1 mice as a highly reproducible immunocompetentpreclinical model to evaluate HIV-1 acquisition across the female genital tract.

UR - http://www.scopus.com/inward/record.url?scp=84940544060&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84940544060&partnerID=8YFLogxK

U2 - 10.1128/JVI.01326-15

DO - 10.1128/JVI.01326-15

M3 - Article

VL - 89

SP - 9559

EP - 9570

JO - Journal of Virology

JF - Journal of Virology

SN - 0022-538X

IS - 18

ER -